EP Patent

EP2900224A1 — Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Assigned to Aragon Pharmaceuticals Inc · Expires 2015-08-05 · 11y expired

What this patent protects

Described herein are anti-androgens for use in treating non-metastatic castrate-resistant prostate cancer

USPTO Abstract

Described herein are anti-androgens for use in treating non-metastatic castrate-resistant prostate cancer

Drugs covered by this patent

Erleada (apalutamide) · Johnson & Johnson

Patent Metadata

Patent number: EP2900224A1
Jurisdiction: EP
Classification: —
Expires: 2015-08-05
Drug substance claim: No
Drug product claim: No
Assignee: Aragon Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.